Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
latest_posts
- 1
German foreign minister heads to China to talk rare-earth exports - 2From White Elephant to Favorite Things parties, here are all the rules you need to know every kind of gift exchange
- 3Congress is running out of time to extend ACA subsidies as the GOP moves on to an alternative plan. Here's where things stand.
- 4Birutė Galdikas: The last of the ‘angels’ in primatology’s most extraordinary chapter
- 5Chemical leak in Oklahoma forces evacuations and leaves many ill
- Catch the moon dancing with bright star Regulus tonight
- Rediscovering Euphoria: Individual Accounts of Conquering Despondency
- Genome study reveals milestone in history of cat domestication
- Sound Maturing: Wellbeing Tips for Each Life Stage
- Canada cancels its 1st moon rover: 'It's hopefully not a lost cause'
- Climate leaders are talking about 'overshoot' into warming danger zone. Here's what it means
- Novartis eyes more bolt-on acquisitions, CEO says
- Tatiana Schlossberg's diagnosis puts spotlight on leukemia: What to know
- Asia's migrant workers debate if Gulf jobs are worth deadly risk of Iran war
